News Releases

This site uses functional cookies and external scripts to improve your experience. Which cookies and scripts are used and how they impact your visit is specified on the left. You may change your settings at any time. Your choices will not impact your visit.

NOTE: These settings will only apply to the browser and device you are currently using.

If you would like to know more about Cookie Notices and Cookie Consent click here

These cookies are required for basic site functionality and are therefore always enabled. These include cookies that allow you to be remembered as you explore the site within a single session or, if you request, from session to session. They help make the shopping cart and checkout process possible as well as assist in security issues and conforming to regulations.

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but if you do so, some parts of the site will not work. These cookies do not store any personal information.

About us

Annual Review 2021

Our work

COMPASS Pathways launches phase 2 clinical trial of psilocybin therapy in anorexia nervosa

Join us

Our team

News & views

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Investors

COMP360 psilocybin therapy in TRD

Responsibility

About us

Impact

About us

News releases

You are now leaving COMPASS Pathways’ website.